<DOC>
	<DOCNO>NCT02954575</DOCNO>
	<brief_summary>The purpose study obtain additional data safety efficacy Wilate PTPs hemophilia A least 150 previous exposure day ( EDs ) FVIII concentrate undergo prophylactic treatment Wilate 6 month least 50 EDs , thus supplement exist database obtain approval Wilate indication hemophilia A USA .</brief_summary>
	<brief_title>Clinical Study Investigate PK , Efficacy , Safety Wilate Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Severe hemophilia A ( &lt; 1 % FVIII : C ) accord medical history 2 . Male patient age ≥12 year 3 . Previous treatment FVIII concentrate least 150 exposure day ( EDs ) 4 . Immunocompetence ( CD4+ count &gt; 200/µL ) 5 . Good documentation historical bleeding rate ( least 6 month precede study start ) 6 . Voluntarily give , fully inform write sign consent obtain patient ( parent/legal guardian case adolescent ) studyrelated procedure conduct 1 . Any coagulation disorder hemophilia A 2 . History FVIII inhibitor activity ( ≥0.6 BU ) detectable FVIII inhibitory antibody ( ≥0.6 BU use Nijmegen modification Bethesda assay ) screening , determined central laboratory 3 . Severe liver kidney disease ( alanine aminotransferase [ ALAT ] aspartate transaminase [ ASAT ] level &gt; 5 time upper limit normal , creatinine &gt; 120 µmol/L ) 4 . Patients receive schedule receive immunomodulating drug ( antiretroviral chemotherapy ) alphainterferon , prednisone ( equivalent &gt; 10 mg/day ) , similar drug 5 . Treatment investigational medicinal product another interventional clinical study currently within 4 week enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>